Diamyd Medical AB (DMYD-B) Fair Value & Analysis
Healthcare · SE · Market cap 176M SEK
Fair value as of: Jul 11, 2026
From 1 valuation models · updated 10 days ago
Share price −0.7% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 1.02 – kr 17.62 · fair‑value band kr 0.8160 – kr 1.54 · the kr 1.08 price screens below the kr 1.23 fair value. As of Jul 11, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Diamyd Medical AB (DMYD-B) currently trades at kr 1.08, while our model-based Fair Value estimate is kr 1.23, implying the stock looks roughly 14.1% undervalued today. We read business quality at 13/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at 362K SEK. Revenue grew 15.1% year over year. The balance sheet holds a net cash position of 277M SEK. Fundamentals as of Jul 11, 2026
Our scenario range runs from kr 0.8160 (bear case) to kr 1.54 (bull case); at kr 1.08, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at 14%, DMYD-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.
About the company
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is headquartered in Stockholm, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Diamyd Medical AB reported revenue of kr 130K in FY2025 versus kr 253K in FY2021, a compound −15.3%/yr. Reported net income was −kr 170M in FY2025.
Is DMYD-B fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 4,803 MXN | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$57.65 | R$9.67 | -83% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$29.70 | HK$26.76 | -10% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Diamyd Medical AB (DMYD-B) undervalued?
What is the fair value of DMYD-B?
What is the quality score of DMYD-B?
What is the revenue of Diamyd Medical AB (DMYD-B)?
What is the net profit margin of DMYD-B?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Diamyd Medical AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.